Literature DB >> 12894245

Caveolae: mining little caves for new cancer targets.

Lucy A Carver1, Jan E Schnitzer.   

Abstract

Caveolae exist at cell surfaces as caveolin-coated invaginations that perform transport and signalling functions influencing cell growth, apoptosis, angiogenesis and transvascular exchange. Caveolin could constitute a key switch in tumour development through its function as a tumour suppressor and as a promoter of metastasis, chemoresistance and survival. Targeting of drugs and gene vectors to tissue-specific proteins in caveolae allows selective delivery into vascular endothelial cells in vivo and might even improve direct access to solid-tumour cells. Therefore, caveolae seem to be rich in potential targets for cancer imaging and therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12894245     DOI: 10.1038/nrc1146

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  74 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 2.  Overcoming key technological challenges in using mass spectrometry for mapping cell surfaces in tissues.

Authors:  Noelle M Griffin; Jan E Schnitzer
Journal:  Mol Cell Proteomics       Date:  2010-06-14       Impact factor: 5.911

3.  Caveolin-1 P132L mutation in human cancers: 1 CAVeat to be voiced.

Authors:  Magali Lacroix-Triki; Felipe Correa Geyer; Jorge Sergio Reis-Filho
Journal:  J Mol Diagn       Date:  2010-06-25       Impact factor: 5.568

4.  Evidence for ectopic aerobic ATP production on C6 glioma cell plasma membrane.

Authors:  Silvia Ravera; Maria Grazia Aluigi; Daniela Calzia; Paola Ramoino; Alessandro Morelli; Isabella Panfoli
Journal:  Cell Mol Neurobiol       Date:  2010-11-17       Impact factor: 5.046

Review 5.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

6.  Screening phage display libraries for organ-specific vascular immunotargeting in vivo.

Authors:  Philippe Valadon; Jeff D Garnett; Jacqueline E Testa; Marc Bauerle; Phil Oh; Jan E Schnitzer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-29       Impact factor: 11.205

7.  Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung.

Authors:  Phil Oh; Per Borgström; Halina Witkiewicz; Yan Li; Bengt J Borgström; Adrian Chrastina; Koji Iwata; Kurt R Zinn; Richard Baldwin; Jacqueline E Testa; Jan E Schnitzer
Journal:  Nat Biotechnol       Date:  2007-03-04       Impact factor: 54.908

8.  PECAM-targeted delivery of SOD inhibits endothelial inflammatory response.

Authors:  Vladimir V Shuvaev; Jingyan Han; Kevin J Yu; Shaohui Huang; Brian J Hawkins; Muniswamy Madesh; Marian Nakada; Vladimir R Muzykantov
Journal:  FASEB J       Date:  2010-09-27       Impact factor: 5.191

9.  CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells.

Authors:  Kei Ohnuma; Tadanori Yamochi; Masahiko Uchiyama; Kunika Nishibashi; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Hirotoshi Tanaka; Nam H Dang; Chikao Morimoto
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

10.  The utilization of pathogen-like cellular trafficking by single chain block copolymer.

Authors:  Gaurav Sahay; Vivek Gautam; Robert Luxenhofer; Alexander V Kabanov
Journal:  Biomaterials       Date:  2009-12-05       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.